| Autor: |
Hermans MP; Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc , Bruxelles , Belgium., Gevaert S; Department of Cardiology, UZ Gent , Gent , Belgium., Descamps O; Department of Internal Medicine, Centre Hospitalier Jolimont, La Louvière, Belgium and Department of Cardiology, UCL Cliniques Universitaires Saint-Luc , Brussels , Belgium., Missault L; Department of Cardiology, AZ St Jan Brugge , Brugge , Belgium., Gillot B; Merck Sharp & Dohme, Corp ., Belgium., De Keyzer D; Merck Sharp & Dohme, Corp ., Belgium., Lautsch D; Merck & Co., Inc ., Kenilworth , NJ , USA., Brudi P; Merck & Co., Inc ., Kenilworth , NJ , USA., Ambegaonkar B; Merck & Co., Inc ., Kenilworth , NJ , USA., Vyas A; Department of Epidemiology, School of Public Health, Rutgers University , Piscataway , NJ , USA., Horack M; Institut für Herzinfarktforschung Ludwigshafen , Ludwigshafen , Germany., Gitt A; Herzzentrum Ludwigshafen, Germany and Institut für Herzinfarktforschung Ludwigshafen , Ludwigshafen , Germany. |
| Abstrakt: |
Objectives : To document the frequency and predictors of low-density lipoprotein cholesterol (LDL-C) target value attainment among patients with coronary heart disease (CHD) in Belgium. Methods : The second Dyslipidemia International Study (DYSIS II) was an observational study of the prevalence of dyslipidemias and lipid target value attainment. Patients in this analysis were aged ≥ 18, had documented CHD, and had a full lipid profile. Use of lipid-lowering therapy (LLT), lipid profile, and LDL-C target value attainment (< 70 mg/dL) were assessed cross-sectionally at the enrollment visit. The distribution of LLTs was assessed among treated patients. Multivariate logistic regression was used to identify variables predictive of LDL-C target value attainment in treated patients. Results : We identified 409 patients with CHD in Belgium, 387 (94.6%) of whom were on LLT at the time of the lipid profile. Among treated patients, the rate of LDL-C target value attainment was 40.6%, and statin monotherapy was the most commonly used LLT (79.3%). Among users of statin monotherapy or combination therapy, simvastatin was the most commonly used treatment (41.6% of patients). Diabetes was associated with higher odds of LDL-C target value attainment (OR 2.29, 95% CI 1.33-3.93), and female gender was associated with lower odds (OR 0.48, 95% CI 0.24-0.97). Conclusion : Rates of LDL-C target value attainment are low in patients with CHD in Belgium. Intensifying statin therapy or combining it with non-statins is essential in Belgian patients for optimal LDL-C reduction. |
